It is reasonable to hypothesize that elevated expression of Osteopontin and its variants in papillomas may be subject to genetic predisposition, such as promoter polymorphisms [30] or interindividual heterogeneity in the splicing machinery, which impose an elevated risk on lesions that might otherwise remain benign and undetected. Here, SPP1 is linked to papilloma.